Midwest Covenant Home | |
615 East 9th Street, Stromsburg, Nebraska 68666 | |
(402) 764-2711 | |
Name | Midwest Covenant Home |
---|---|
Location | 615 East 9th Street, Stromsburg, Nebraska |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 52 |
Occupancy Rate | 47.5% |
Medicare ID (CCN) | 285062 |
Legal Business Name | Midwest Covenant Home, Inc. |
Ownership Type | Non Profit - Corporation |
NPI Number | 1326047697 |
Organization Name | MIDWEST COVENANT HOME, INC. |
Doing Business As | MIDWEST COVENANT HOME, INC. |
Address | 615 E 9th St, Stromsburg, NE 68666 |
Phone Number | 402-764-2711 |
News Archive
miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today the formation of the company's world renowned Scientific Advisory Board (SAB). The SAB was established to provide miRagen with valuable guidance in developing an extensive pipeline of microRNA-based drugs and is comprised of leaders who are internationally recognized experts in their respective fields.
Exciting data from the 26th European Society of Thoracic Surgeons meeting shows an association between innovation, and improved patient outcomes and lowered hospital costs
A study conducted by Hiroshima University researchers found that using Ultraviolet C light with a wavelength of 222 nanometers which is safer to use around humans effectively kills SARS-CoV-2 - the first research in the world to prove its efficacy against the virus that causes COVID-19.
The U.S. Food and Drug Administration approved Afinitor (everolimus), the first drug approved specifically to treat non-cancerous kidney tumors (renal angiomyolipomas) not requiring immediate surgery in patients with tuberous sclerosis complex.
A new study on the age of initial breast development as the first sign of puberty in girls shows that over the last 40 years, this has come down by an average of 3 months per decade. The study is published in the journal Pediatrics.
› Verified 4 days ago
NPI Number | 1962799320 |
Organization Name | MIDWEST COVENANT HOME, INC. |
Doing Business As | MIDWEST COVENANT HOME OTHS |
Address | 615 E 9th St, Stromsburg, NE 68666 |
Phone Number | 402-764-2711 |
News Archive
miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today the formation of the company's world renowned Scientific Advisory Board (SAB). The SAB was established to provide miRagen with valuable guidance in developing an extensive pipeline of microRNA-based drugs and is comprised of leaders who are internationally recognized experts in their respective fields.
Exciting data from the 26th European Society of Thoracic Surgeons meeting shows an association between innovation, and improved patient outcomes and lowered hospital costs
A study conducted by Hiroshima University researchers found that using Ultraviolet C light with a wavelength of 222 nanometers which is safer to use around humans effectively kills SARS-CoV-2 - the first research in the world to prove its efficacy against the virus that causes COVID-19.
The U.S. Food and Drug Administration approved Afinitor (everolimus), the first drug approved specifically to treat non-cancerous kidney tumors (renal angiomyolipomas) not requiring immediate surgery in patients with tuberous sclerosis complex.
A new study on the age of initial breast development as the first sign of puberty in girls shows that over the last 40 years, this has come down by an average of 3 months per decade. The study is published in the journal Pediatrics.
› Verified 4 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today the formation of the company's world renowned Scientific Advisory Board (SAB). The SAB was established to provide miRagen with valuable guidance in developing an extensive pipeline of microRNA-based drugs and is comprised of leaders who are internationally recognized experts in their respective fields.
Exciting data from the 26th European Society of Thoracic Surgeons meeting shows an association between innovation, and improved patient outcomes and lowered hospital costs
A study conducted by Hiroshima University researchers found that using Ultraviolet C light with a wavelength of 222 nanometers which is safer to use around humans effectively kills SARS-CoV-2 - the first research in the world to prove its efficacy against the virus that causes COVID-19.
The U.S. Food and Drug Administration approved Afinitor (everolimus), the first drug approved specifically to treat non-cancerous kidney tumors (renal angiomyolipomas) not requiring immediate surgery in patients with tuberous sclerosis complex.
A new study on the age of initial breast development as the first sign of puberty in girls shows that over the last 40 years, this has come down by an average of 3 months per decade. The study is published in the journal Pediatrics.
› Verified 4 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 1 |
Total Amount of Fines in Dollars | $7760 |
Number of Payment Denials | 0 |
Total Number of Penalties | 1 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 17.39 | 14.46 |
Percentage of long-stay residents who lose too much weight | 1.49 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 73.33 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.31 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 3.03 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 2.02 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 8.74 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 90.29 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 17.39 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 73.02 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 23.1 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 18.31 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 3.53 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.6 | 95.98 |